Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Large Growth in Short Interest

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 65,538 shares, a growth of 327.4% from the July 15th total of 15,334 shares. Approximately 1.2% of the company’s shares are short sold. Based on an average daily volume of 638,720 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of Neuphoria Therapeutics

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of Neuphoria Therapeutics by 33.3% during the fourth quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock worth $67,000 after acquiring an additional 4,325 shares in the last quarter. Persistent Asset Partners Ltd lifted its position in Neuphoria Therapeutics by 173.1% in the 4th quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after acquiring an additional 8,495 shares in the last quarter. Merck & Co. Inc. bought a new position in Neuphoria Therapeutics in the 2nd quarter valued at about $43,818,000. Commonwealth Equity Services LLC bought a new stake in Neuphoria Therapeutics during the 4th quarter worth approximately $43,000. Finally, XTX Topco Ltd bought a new stake in Neuphoria Therapeutics during the 4th quarter worth approximately $47,000. 15.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. Wall Street Zen raised shares of Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 25th. Finally, HC Wainwright lowered shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Neuphoria Therapeutics has an average rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Stock Performance

Shares of NASDAQ NEUP traded up $0.04 during midday trading on Friday, hitting $3.87. 23,708 shares of the company’s stock traded hands, compared to its average volume of 106,869. Neuphoria Therapeutics has a 1 year low of $3.19 and a 1 year high of $21.40. The stock has a market capitalization of $20.90 million, a price-to-earnings ratio of -0.35 and a beta of 0.75. The firm has a fifty day moving average of $3.93 and a 200 day moving average of $4.37.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. On average, equities analysts anticipate that Neuphoria Therapeutics will post -4.07 earnings per share for the current year.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.